• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism.近期发生静脉血栓栓塞的成年患者抗血栓药物使用模式的描述性研究。
Pharm Pract (Granada). 2019 Jul-Sep;17(3):1539. doi: 10.18549/PharmPract.2019.3.1539. Epub 2019 Aug 22.
2
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.直接口服抗凝剂与传统抗凝剂在静脉血栓栓塞症中的安全性。
J Thromb Thrombolysis. 2019 Oct;48(3):439-453. doi: 10.1007/s11239-019-01878-x.
3
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.复发性静脉血栓栓塞和大出血的病死率与阿司匹林、华法林和直接口服抗凝剂用于二级预防相关。
Thromb Res. 2015 Feb;135(2):243-8. doi: 10.1016/j.thromres.2014.10.033. Epub 2014 Dec 2.
4
Evaluation of anticoagulation selection for acute venous thromboembolism.急性静脉血栓栓塞症抗凝治疗选择的评估
J Thromb Thrombolysis. 2017 Jan;43(1):74-78. doi: 10.1007/s11239-016-1417-5.
5
Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.直接口服抗凝剂与华法林治疗伴有活动性癌症的静脉血栓栓塞症患者的有效性和安全性比较:一项观察性分析。
Clin Ther. 2020 Sep;42(9):e161-e176. doi: 10.1016/j.clinthera.2020.06.022. Epub 2020 Aug 4.
6
Anticoagulation prescribing patterns in patients with cancer.癌症患者的抗凝药物处方模式。
J Thromb Thrombolysis. 2018 Jan;45(1):89-98. doi: 10.1007/s11239-017-1558-1.
7
Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching study.从维生素 K 拮抗剂转换一年后,直接口服抗凝剂的依从性和患者体验探索——转换研究的见解。
Thromb Res. 2018 Feb;162:62-68. doi: 10.1016/j.thromres.2017.12.021. Epub 2018 Jan 2.
8
Associations between anticoagulant treatment pathways and self-reported harms in patients recently diagnosed with venous thromboembolism.近期诊断为静脉血栓栓塞症患者的抗凝治疗途径与自我报告伤害之间的关联。
Thromb Res. 2019 Oct;182:95-100. doi: 10.1016/j.thromres.2019.08.006. Epub 2019 Aug 13.
9
Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.静脉血栓栓塞症抗凝延长治疗患者换用直接口服抗凝剂后对患者满意度的影响:SWAN 研究。
PLoS One. 2020 Jun 4;15(6):e0234048. doi: 10.1371/journal.pone.0234048. eCollection 2020.
10
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism.抗凝治疗对华法林和直接口服抗凝剂治疗静脉血栓栓塞的满意度。
J Thromb Thrombolysis. 2021 Nov;52(4):1101-1109. doi: 10.1007/s11239-021-02437-z. Epub 2021 Apr 8.

引用本文的文献

1
Α 6-month, multicenter, observational study investigating the treatment of venous thromboembolism in Greece (VICTORIA study).一项为期6个月的多中心观察性研究,旨在调查希腊静脉血栓栓塞症的治疗情况(维多利亚研究)。
Thromb J. 2025 Jun 23;23(1):71. doi: 10.1186/s12959-025-00749-1.
2
Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real-World Practice Mirrors Guideline Recommendations.诱发型静脉血栓栓塞症抗凝治疗的时长:真实世界实践与指南推荐相符程度的多中心研究。
J Am Heart Assoc. 2022 Nov;11(21):e025471. doi: 10.1161/JAHA.122.025471. Epub 2022 Oct 26.
3
Venous thromboembolism prevention protocol for adapting prophylaxis recommendations to the potential risk post total knee replacement: a randomized controlled trial.全膝关节置换术后根据潜在风险调整预防建议的静脉血栓栓塞预防方案:一项随机对照试验
Pharm Pract (Granada). 2020 Jul-Sep;18(3):2025. doi: 10.18549/PharmPract.2020.3.2025. Epub 2020 Sep 22.

本文引用的文献

1
Outcomes associated with a change in clinical practice to alleviate emotional harm related to venous thromboembolism.与改变临床实践以减轻与静脉血栓栓塞相关的情感伤害相关的结果。
Thromb Res. 2019 Aug;180:29-31. doi: 10.1016/j.thromres.2019.05.022. Epub 2019 Jun 1.
2
Understanding patients' care barriers in the treatment of venous thromboembolism.了解静脉血栓栓塞症治疗中患者的护理障碍。
J Thromb Thrombolysis. 2019 Jul;48(1):35-41. doi: 10.1007/s11239-019-01880-3.
3
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28.
4
Prevalence and correlates of bleeding and emotional harms in a national US sample of patients with venous thromboembolism: A cross-sectional structural equation model.在美国静脉血栓栓塞患者的全国样本中,出血和情绪伤害的流行情况及其相关性:一项横断面结构方程模型研究。
Thromb Res. 2018 Dec;172:181-187. doi: 10.1016/j.thromres.2018.05.025. Epub 2018 May 23.
5
Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation.老年房颤患者华法林和直接口服抗凝剂的使用趋势
Am J Health Syst Pharm. 2017 Aug 15;74(16):1237-1244. doi: 10.2146/ajhp160756. Epub 2017 Jun 26.
6
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.抗栓治疗 VTE 疾病:CHEST 指南和专家小组报告。
Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7.
7
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism.华法林治疗静脉血栓栓塞症的实际管理指南。
J Thromb Thrombolysis. 2016 Jan;41(1):187-205. doi: 10.1007/s11239-015-1319-y.
8
The epidemiology of venous thromboembolism.静脉血栓栓塞症的流行病学
J Thromb Thrombolysis. 2016 Jan;41(1):3-14. doi: 10.1007/s11239-015-1311-6.
9
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art.深静脉血栓形成和肺栓塞的抗凝治疗:现状。
Front Cardiovasc Med. 2015 Jul 14;2:30. doi: 10.3389/fcvm.2015.00030. eCollection 2015.
10
Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective.复发性静脉血栓栓塞的经济负担:从美国医院角度的分析
Am J Health Syst Pharm. 2015 Feb 15;72(4):291-300. doi: 10.2146/ajhp140204.

近期发生静脉血栓栓塞的成年患者抗血栓药物使用模式的描述性研究。

A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism.

作者信息

Allahwerdy Fady, Pan Steven, Feehan Michael, Jones Aubrey E, Munger Mark A, Witt Daniel M

机构信息

Department of Pharmacotherapy, College of Pharmacy, University of Utah. Salt Lake City, UT (United States).

Kantar LLC, San Francisco, CA (United States).

出版信息

Pharm Pract (Granada). 2019 Jul-Sep;17(3):1539. doi: 10.18549/PharmPract.2019.3.1539. Epub 2019 Aug 22.

DOI:10.18549/PharmPract.2019.3.1539
PMID:31592294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6763305/
Abstract

OBJECTIVES

The objective of this study is to describe the most common self-reported antithrombotic therapy utilization patterns in a national cohort of patients with recent venous thromboembolism (VTE).

METHODS

Extant data from a national online survey administered to 907 patients 18 years of age or older with VTE in the last two years were analyzed. Patients' self-reported antithrombotic usage patterns used during three phases of treatment for the most recent VTE episode were summarized using descriptive statistics.

RESULTS

The following overall antithrombotic usage patterns were identified: warfarin (38.7%), direct oral anticoagulants (DOACs) (26.1%), switching between warfarin and DOACs (13.3%), aspirin only (8.7%), switching between different DOACs (4.5%), injectable anticoagulants only (3.9%), and no treatment (4.7%). Extended antithrombotic therapy beyond 90 days was reported by 65.7% of patients. Aspirin coadministration with anticoagulant therapy occurred for 33.7%.

CONCLUSIONS

In this national sample of recent VTE sufferers warfarin therapy remains the most used anticoagulant followed closely by DOAC therapy. Switching between warfarin and DOACs and between different DOACs was common which could indicate adverse events or affordability issues. Aspirin coadministration with anticoagulant therapy was present in 1 of 3 patients and is a potential medication safety intervention for anticoagulation providers.

摘要

目的

本研究的目的是描述全国近期静脉血栓栓塞症(VTE)患者队列中最常见的自我报告的抗血栓治疗使用模式。

方法

对一项针对过去两年内907名18岁及以上VTE患者进行的全国在线调查的现有数据进行分析。使用描述性统计方法总结了患者在最近一次VTE发作的三个治疗阶段中自我报告的抗血栓药物使用模式。

结果

确定了以下总体抗血栓药物使用模式:华法林(38.7%)、直接口服抗凝剂(DOACs)(26.1%)、在华法林和DOACs之间切换(13.3%)、仅使用阿司匹林(8.7%)、在不同DOACs之间切换(4.5%)、仅使用注射用抗凝剂(3.9%)以及未进行治疗(4.7%)。65.7%的患者报告了超过90天的延长抗血栓治疗。33.7%的患者将阿司匹林与抗凝治疗联合使用。

结论

在这个全国性的近期VTE患者样本中,华法林治疗仍然是使用最广泛的抗凝剂,紧随其后的是DOAC治疗。在华法林和DOACs之间以及不同DOACs之间的切换很常见,这可能表明存在不良事件或可负担性问题。三分之一的患者将阿司匹林与抗凝治疗联合使用,这对抗凝治疗提供者来说是一种潜在的药物安全干预措施。